瑞舒伐他汀治疗冠心病合并高脂血症的疗效及对血清hs-CRP的影响

Effect of rosuvastatin on coronary heart disease combined with hyperlipidemia and its influence on serum high-sensitivity C-reactive protein

目的分析瑞舒伐他汀对冠心病合并高脂血症患者的治疗效果及对血清超敏C-反应蛋白(hs-CRP)的影响。方法选取2018年1月—2019年4月阳谷县人民医院103例冠心病合并高脂血症患者作为研究对象,按照数字分组法分为治疗组(n=52)和对照组(n=51)。对照组应用阿托伐他汀治疗,治疗组应用瑞舒伐他汀治疗,对比两组治疗前后血脂水平、血清hs-CRP、颈动脉内中膜厚度(IMT)。结果治疗后,两组hs-CRP水平均降低,治疗组hs-CRP水平(2.08±0.45)mmol/L低于对照组的(5.84±1.12)mmol/L,差异有统计学意义(P<0.05)。治疗前,两组甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P>0.05);治疗后,两组TG、TC、LDL-C和HDL-C水平均有改善,且治疗组优于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,治疗组IMT水平(0.60±0.22)mm,低于对照组的(0.84±0.13)mm,差异有统计学意义(P<0.05)。结论冠心病合并高脂血症患者应用瑞舒伐他汀可对血脂水平进行有效调节,并降低hs-CRP水平,有较高的用药价值和安全性。

Objective To analyze the therapeutic effect of rosuvastatin on patients with coronary heart disease combined with hyperlipidemia and its effect on serum high-sensitivity C-reactive protein(hsCRP).Methods From January 2018 to April 2019,103 patients with coronary heart disease combined with hyperlipidemia in Yanggu County People’s Hospital were selected as the research subjects and were divided into treatment group(n=52)and control group(n=51).The control group was treated with atorvastatin,and the treatment group was treated with rosuvastatin.The blood lipid levels,serum hs-CRP,and carotid intima-media thickness(IMT)were compared between the two groups before and after treatment.Results After treatment,the levels of hs-CRP in the two groups were decreased.The level of hs-CRP in the treatment group was statistically lower than that in the control group[(2.08±0.45)mmol/L vs.(5.84±1.12)mmol/L,P<0.05].Before treatment,there was no significant difference in the levels of TG,TC,LDL-C and HDL-C between the two groups(all P>0.05).After treatment,the levels of TG,TC,LDL-C and HDL-C in both groups were improved,especially in the treatment group(all P<0.05).The difference between the two groups was statistically significant(P<0.05).After treatment,the IMT level in the treatment group was(0.60±0.22)mm,which was lower than that in the control group[(0.84±0.13)mm],and the difference was statistically significant(P<0.05).Conclusion The use of rosuvastatin in patients with coronary heart disease and hyperlipidemia can effectively regulate blood lipid levels and reduce hs-CRP levels,which has high drug value and safety.